Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in Belgium / NCT06445361
Recruiting Not applicable

Prevalence of NAFLD in T1DM Patients

NCT06445361 · tracked via the Priya Life Science Belgium tracker
Sponsor
Ziekenhuis Oost-Limburg
Phase
Not applicable
Started
2023-07-01
Last updated
2025-07-28

Condition(s) studied

NAFLDType 1 DiabetesFatty Liver, Nonalcoholic

Investigational drug(s) / intervention(s)

FibroScan

FibroScan: Performance of a FibroScan measurement to determine steatosis and fibrosis.

Study summary

To determine the prevalence of NAFLD in T1DM patients.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * T1DM * ≥ 18 years of age * Written informed consent obtained Exclusion Criteria: * Excessive alcohol use * Exclusion of other causes of liver disease and secondary causes of liver steatosis

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
Ziekenhuis Oost-Limburg Genk Limburg Recruiting

More Ziekenhuis Oost-Limburg trials in Belgium

PRotEin Provision in Critical IllneSs -2 Starting soon
The Impact of IV Iron on Exercise Capacity and Quality of Life in Pulmonary Hypertension Recruiting
Prevalence of NAFLD in T2DM Patients Active, not recruiting
The Effect of Corticosteroids on Quality of Life Following Total Hip Arthroplasty: HIPSTER Study Recruiting
Synbiotics in Patients at RIsk fOr Preterm Birth Recruiting

Other trials for the same condition

Prevalence of NAFLD in T2DM Patients Active, not recruiting
Prevalence of Non-Alcoholic Fatty Liver Disease in Inflammatory Bowel Disease Patients Recruiting
Real-World Study of Patients With Type 1 Diabetes Treated With Teplizumab as Part of Managed Access Programs (MAPs) Recruiting
SAFety and Efficacy of Human Anti-thymocyte ImmunoGlobUlin SAB-142 ARresting Progression of Type 1 Diabetes Recruiting
The European NAFLD Registry Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06445361 on ClinicalTrials.gov ↗ ← All trials in Belgium